Transplantation & cellular therapy Meetings of ASTCT & CIBMTR

Three abstracts demonstrate the safety and efficacy briquilimab when combined with low-toxicity radiation conditioning in order to attain full donor engraftment.

• Data show that briquilimab is well-tolerated and safe as a condition agent in older patients. Median age is 70 for AML/MDS who are undergoing allogeneic stem cell transplantation.

• Durable remissions were achieved in 8 out of 12 AML patients at the one-year follow-up

• 29 AML/MDS patients had lower rates than expected of severe, acute and chronic graft–vs-host diseases

• Report on 12 patients who were treated at one center for outpatient treatment and donor cell transplant. This has been associated with lower hospital resources.

REDWOOD CITY, Calif., Jan. 13, 2023 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a biotechnology company developing novel antibody therapies addressing chronic diseases such as urticaria, lower-risk myelodysplastic syndromes (MDS) and stem cell transplant conditioning agents targeting c-Kit, today announced that new positive data for briquilimab (formerly known as JSP191), will be presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, taking place on February 15-19, 2023 in Orlando, Florida.

Three abstracts will be presented that cover data from the Phase 1 study on briquilimab combined with fludarabine (low-dose radiation (Flu/TBI), conditioning in older adults (62–79 years) with acute and chronic myeloid leukemias (AML) and MDS undergoing allogeneic hemotopoietic cell transplantation (HCT). Studies show that the combination of fludarabine and briquilimab results in successful engraftment. This is in contrast to other busulfan-based regimens that are commonly used for transplant of donor cells or gene-corrected ones. Briquilimab’s mechanism of action is that it can enhance its stem cell depleting effects while reducing off-target toxicities.

The first abstract shows that briquilimab can be safely administered and is well tolerated. In 8 out of 12 patients with AML, the drug achieved lasting remissions. At one year follow-up, all 8 patients experienced no relapses. Sixteen of nine patients with detectable AML entered transplant. This group is known for having a poor prognosis and high relapse rates. A companion abstract revealed that 29 AML/MDS patients who received flu/TBI and briquilimab had lower rates than expected of chronic and acute graft-versus host disease (GVHD). The Best Abstract session’s third abstract will examine the healthcare utilization and costs of 12 briquilimab + Flu/TBI patients who received both outpatient conditioning and donor-cell transplant at one center. In the 100-day period following the procedure, there were 7 hospitalizations for each patient. The average length of stay was 4 days. These results show the potential cost savings and feasibility of outpatient briquilimab plus Flu/TBI treatment followed by outpatient transplantation of donor cells in older patients with AML/MDS.

“Our data presentations at the ASTCT meeting add to the significant body of clinical evidence supporting the safety and clinical potential of briquilimab in a variety of indications and patient types,” said Ronald Martell, President and Chief Executive Officer of Jasper. “While we are focusing our near-term resources on the development of briquilimab for chronic diseases and as a conditioning agent for stem cell transplants addressing rare diseases, we believe these data demonstrate that briquilimab is an agent that can markedly improve the safety and efficacy of stem cell transplants for a wide range of malignant and rare diseases.”

Abstract details:

About Briquilimab (formerly JSP191)

Briquilimab (or CD117) is a monoclonal targeted antibody that inhibits the cell surface receptor cKit. It is being tested as a primary therapy for mast cell disorders such as chronic spontaneous and chronic inducible, allergic urticaria (CIndU), as well as for patients at lower risk of MDS. It is also being evaluated as a conditioning agent for gene and cell therapies for rare diseases. Briquilimab has been shown to be safe and effective in 130 patients and healthy volunteers. It also showed clinical results as a conditioning agent in severe mixed immunodeficiency (SCID), acute meeloid leukemia, myelodysplastic disorders (MDS), Fanconi and sickle cells (SCD). Briquilimab has been developed as a non-toxic transformational conditioning agent for gene therapies.

Jasper

Jasper is a biotechnology company in clinical stages that develops novel antibodies and stem cell transplant conditioning agent targeting cKit (CD117), a crucial receptor found on stem cells. The Company’s lead program is briquilimab, a first-in-class monoclonal antibody being developed as a therapeutic for chronic diseases and as a conditioning agent for stem cell transplants for rare diseases. For more information, please visit us at jaspertherapeutics.com.

Forward-Looking Statements

For the safe harbor provisions under 1995’s United States Private Securities Litigation Reform Act, forward-looking statements may be included in this release. Forward-looking statements are sometimes accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Jasper’s plans with respect to its near-term resources and briquilimab’s potential, including with respect to cost savings and any ability for it to improve the safety and efficacy of stem cell transplants for a range of malignant and rare diseases. These statements are based on various assumptions and current expectations of Jasper. They are not predictions of actual performance. These forward-looking statements are intended for illustration purposes only. Investors should not rely on them as a guarantee or assurance or as a prediction of future events or facts. Jasper cannot predict the future and many events and circumstances could occur. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jasper’s product candidates may not be beneficial to patients or successfully commercialized; patients’ willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper’s business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper’s business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics, including the ongoing COVID-19 pandemic; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or Jasper’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. Jasper could choose to make future updates to these forward-looking statements, but Jasper expressly disclaims any obligation. These forward-looking statements should not be relied upon as representing Jasper’s assessments of any date subsequent to the date of this press release. The forward-looking statements shouldn’t be relied on in any way.

Contacts:
John Mullaly (investors)
LifeSci Advisors
617-429-3548
[email protected]

Jeet Mahal, (investors).
Jasper Therapeutics
650-549-1403
[email protected]

Lauren Barbiero (media)
Real Chemistry
646-564-2156
[email protected]